Justine Pasanisi
Overview
Explore the profile of Justine Pasanisi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bello R, Pacchiardi K, Chauvel C, Ades L, Braun T, Pasanisi J, et al.
Hemasphere
. 2022 Dec;
7(1):e819.
PMID: 36570694
No abstract available.
2.
Duchmann M, Joudinaud R, Boudry A, Pasanisi J, Di Feo G, Kim R, et al.
Blood Cancer J
. 2022 Sep;
12(9):136.
PMID: 36151081
No abstract available.
3.
Bello R, Pasanisi J, Joudinaud R, Duchmann M, Pardieu B, Ayaka P, et al.
Blood Cancer J
. 2022 Jun;
12(6):95.
PMID: 35750691
Functional precision medicine in AML often relies on short-term in vitro drug sensitivity screening (DSS) of primary patient cells in standard culture conditions. We designed a niche-like DSS assay combining...
4.
Pardieu B, Pasanisi J, Ling F, Bello R, Penneroux J, Su A, et al.
Leukemia
. 2022 Apr;
36(6):1585-1595.
PMID: 35474100
By querying metabolic pathways associated with leukemic stemness and survival in multiple AML datasets, we nominated SLC7A11 encoding the xCT cystine importer as a putative AML dependency. Genetic and chemical...
5.
Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Bello R, et al.
Cancer Discov
. 2020 Aug;
10(12):1894-1911.
PMID: 32826232
Deciphering the impact of metabolic intervention on response to anticancer therapy may elucidate a path toward improved clinical responses. Here, we identify amino acid-related pathways connected to the folate cycle...
6.
Cerrano M, Duchmann M, Kim R, Vasseur L, Hirsch P, Thomas X, et al.
Leukemia
. 2020 Jun;
35(3):712-723.
PMID: 32581253
Intra-tumor heterogeneity portends poor outcome in many cancers. In AML, a higher number of drivers worsens prognosis. The Shannon Index is a robust metric of clonal heterogeneity that accounts for...
7.
Masse A, Roulin L, Pasanisi J, Penneroux J, Gachet S, Delord M, et al.
Leuk Res
. 2019 Nov;
87:106269.
PMID: 31751766
Bromodomain and Extra-Terminal inhibitors (BETi) such as OTX015 are active in Acute Myeloid Leukaemias (AML). Their activity on Leukemic Stem Cells (LSCs) is less documented. We interrogated the anti-LSC activity...